1. To test whether topical rapamycin regresses established keloids in humans by measuring
surface area and height changes in the scar over time (6 months)
2. To test safety of product and feasibility of conduct for future clinical trial
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio